Innovation Pharmaceuticals Inc (IPIX)

[RJFL]

Hi KMBJN, I agree with most of your post and while I do think we need to temper expectations with regards to the pancreatic cancer patients response to Kevetrin, I believe statistics you mention regarding PFS could be a bit misleading. While I take you at your word that those numbers are accurate for pancreataic cancer patients, they probably refer to initial treatments and not for those who failed a treatment and then started a second form of treatment and thus their cancer is growing again. Since one of the requirements for inclusion in the Phase I Kevetrin trial is:

either refractory after standard therapy, or for which no effective curative or surgical treatment options are available

There is a resonable chance that the panceratic cancer patient who had the 4 month stabilization was someone who had already gone thru standard/earlier treatment and now had refractory disease and then achived a second 4 month stabilization. That is the aspect that would make it notable if indeed the patient had failed earlier treatment. No way of knowing but hopefully that's the case.